 Oncocyte Corporations NASDAQ: OCX Q2 revenues were 2.03 million, compared to 143,000 in Q2 FY20 and beating consensus of 1.57 million. Most revenues were attributable to tech transfer under a December licensing deal with Burning Rock Biotech for Oncocytes DetermaRx lung cancer test. 